Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations

In this article, we explore regulatory developments in stem cell medicine in seven jurisdictions: Japan, China, India, Argentina, Brazil, the USA and the EU. We will show that the research methods, ethical standards and approval procedures for the market use of clinical stem cell interventions are undergoing an important process of global diversification. We will discuss the implications of this process for international harmonization and the conduct of multicountry clinical research collaborations. It will become clear that the increasing heterogeneity of research standards and regulations in the stem cell field presents a significant challenge to international clinical trial partnerships, especially with countries that diverge from the regulatory models that have been developed in the USA and the EU.

First draft submitted: 15 June 2016; Accepted for publication: 12 August 2016; Published online: 13 September 2016

Keywords: clinical stem cell research • evidence-based medicine • international harmonization • multicountry trials • research regulation

The regulatory conditions through which stem cell treatments are translated from the laboratory bench to the clinic and the market are currently in the midst of a renegotiation process [1–3]. A key problem for the stem cell field is that existing regulatory approaches for the clinical testing and market approval of new drugs do not neatly map onto stem cell interventions. The biological characteristics of stem cells and specific risks for patients require new and tailor-made regulatory frameworks to reliably address scientific and health risks [4]. But the development of regulatory frameworks for stem cell medicine has also been complicated by the widespread availability of unproven or nonsystematically tested for-profit interventions with stem cells in many countries [5]. Lucrative business opportunities and widespread demands of patients have resulted in calls for increased access to experimental stem cell interventions and the development of regulatory alternatives. Disagreements have arisen in particular with regard to the acceptability of experimental stem cell interventions outside of the methodological format of the multiphase randomized controlled trial (RCT), and also the provision of experimental therapies independent from the review of drug regulatory authorities.

The position of the International Society for Stem Cell Research, as published in its recent Guidelines for Stem Cell Research and Clinical Translation, is that “stem cell-based medical products should rarely if ever be developed outside of a formal clinical trials process” [6]. The International Society for Stem Cell Research acknowledges, though, “that in some very limited cases, clinicians may be justified in attempting medically innovative stem cell-based interventions in a small number of seriously ill patients.” However, providers of experimental stem cell interventions should “under no circumstances” be allowed to “promote, advertise, attempt general recruitment of patients or commercialize such interventions” [6].

Achim Rosemann*,1,2, Gabriela Bortz3,4, Federico Vasen3,5 & Margaret Sleeboom-Faulkner2,6
1Centre for Education Studies, Faculty of Social Sciences, University of Warwick, Coventry, CV4 7AL, UK
2Centre for Bionetworking, School of Global Studies, University of Sussex, Brighton, BN1 9SJ, UK
3Institute of Science & Technology Studies, National University of Quilmes (IESCT-UNQ), Roque S. Peña 352, (1876) Bernal, Buenos Aires, Argentina
4National Council of Scientific & Technical Research (CONICET), Godoy Cruz 2290, C1425FQB Buenos Aires, Argentina
5Institute of Social Research, National Autonomous University of Mexico, Circuito Mario de la Cueva s/n, Ciudad Universitaria, Coyoacán, 04510 Ciudad de México, Mexico
6Department of Anthropology, University of Sussex, Arts C 206, Brighton, BN1 9SJ, UK

*Author for correspondence: a.rosemann@warwick.ac.uk
On the other hand, guidelines from other international societies, such as the International Cellular Medicine Society [7] or the International Association of Neurorestoratology [8], have argued in favor of clinical applications outside of the multiphase clinical trial system [3]. In practice, the provision of commercial clinical stem cell interventions that are offered to patients without systematic clinical research continues to occur on a large scale. McMahon has, in this respect, spoken of the rise of a ‘global industry’ of unproven or nonsystematically tested stem cell interventions [5]. She has estimated that in the last 15 years or so several hundred thousands of patients have received experimental stem cell interventions.

In Part I of this article, we will explore how regulatory authorities in the above-mentioned jurisdictions have reacted to these developments. The questions we ask are: what are current developments and trends in the regulation of clinical stem cell interventions and in which ways do these developments challenge the dominant paradigm of evidence-based medicine (EBM) and multiphase controlled trials in clinical stem cell research. We will show that, even though the clinical evaluation and market approval of stem cell interventions through EBM standards and the use of the multiphase RCT system are still important in many countries, a continuing process of regulatory diversification is underway. Moreover, regulatory arrangements are still evolving in many societies, which have given rise to uncertainties, and which have made efforts of international harmonization more difficult. As we will show that the shift toward regulatory diversification is characterized by three central processes: first, an increasing number of regulatory exceptions and exemptions that allow for clinical applications with stem cells outside of the multiphase trial system; second, lenient enforcement of regulatory rules in many countries, which has resulted in the widespread toleration of experimental for-profit practices despite the fact that official regulatory protocols impose the mandatory use of RCTs; third, the emerging of entirely new regulatory models. This is most clearly exemplified by the case of Japan, which in 2014 introduced a model of conditional market approval for stem cell products that allows sideling the Phase I–III clinical trials system.

In Part II, we will explore the implications of these processes for international harmonization and the conduct of international clinical research collaborations. We will show that the absence of internationally binding standards for clinical stem cell research presents a huge challenge to multicountry clinical trial partnerships.

## Regulatory comparison

### USA

The USA was the first country to have issued a formal regulation for clinical use and market approval of stem cell interventions. The US FDA rules went into effect with the interim rule Human Cells, Tissues, and Cellular and Tissue-Based Products: Donor Screening and Testing, and Related Labeling, which was issued on 25 May 2005 [9]. On 19 June 2007, this interim rule was adopted as a final rule, without change, and released as the FDA’s Regulation For Human, Cellular and Tissue Products (HCT/Ps) [10]. This regulatory framework introduced a risk-based, tiered approach that regulates stem cells as biological products within two categories: ‘351 products’ and ‘361 products’ [10]. The ‘351’ category refers to cells that are more than minimally manipulated and to cells that are used in a nonhomologous manner. These cells are classified as a biological drug product and they are subject to FDA premarket approval. 351 biological products must “by law […] go through the multiphase drug pipeline approval process starting after preclinical studies with an investigational new drug application and proceeding to Phase I trials” and then to Phase II and III trials [11].

In a recent effort to create more flexible pathways to market approval of new drugs and biological products, the FDA has introduced, since 2012, three types of regulatory exceptions, which can also be granted to human cell and tissue products [11]. These exceptions aim at: first, speeding up the transition from preclinical to clinical testing (‘fast track approval’) [12]; second, accelerated authorization of Phase I and II clinical trials that involve seriously ill patients with low life expectancy (‘accelerated approval’) [13] and third, more rapid clinical testing of ‘breakthrough therapies’ that have the potential to treat a serious or potentially life-threatening disease (‘breakthrough therapy designation’) [14]. In addition to these more recent regulatory exceptions, the FDA offers also a ‘priority review’ procedure, which was introduced in 1992. Priority review aims to expedite the duration of the evaluation process that precedes market approval of a new drug (6 instead of 10 months), after the completion of the clinical trial period [15]. A fifth regulatory exception is the ‘expanded access’ program (also called ‘compassionate use program’). This program provides patients access to investigational new treatments parallel to (but outside of) FDA-approved Phase II and III clinical trials [16]. The expanded use program dates back to 1987 but was revised in 2009 to ensure “broad and equitable access to investigational drugs for treatment,” including access to biological drug products [17].
The ‘361’ category regulates the use of minimally manipulated stem cells that are applied for homologous use. These cells are not subject to premarket approval by the FDA and they can be used in patients under compliance with the US human tissue regulation [18]. A large direct-to-consumer (DTC) market with ‘361’ stem cell products has emerged in the USA in recent years [11]. While many of these clinics purport to offer self-classified ‘361’ products, there have been reports that several of these interventions were actually unproven ‘351’ products, which were offered to patients illegally [11]. In response to these claims, the FDA published in November 2015 a draft guidance for a revised and more stringent regulatory approach, which was designed to address this problem [19,20]. At the time of writing this article, though, this draft guidance was not yet finalized.

EU
Regulatory arrangements for stem cell treatments in the EU are similar to the US model. Cells that are more than minimally manipulated and used in non-homologous contexts are defined as ‘medicinal products’ and are regulated under the Advanced Therapy Medicinal Products (ATMPs) legislation, which was issued by the EMA in November 2007. Minimally manipulated autologous stem cells, on the other hand, are regulated under the human tissue legislations of European member states, and not centrally under EMA [21]. The ATMP regulation has harmonized regulatory approaches for clinical stem cell research in EU member states, to enable clinical collaborations and cross-country approval of stem cell products outside of the EU. As in the USA, the EMA regulation demands evidence from systematic clinical studies, typically from multiphase trials. In contrast to the USA, the EU has not experienced the emerging of a large-scale consumer market with minimally manipulated stem cells [22]. However, demands of patients to widen access to stem cell interventions have been addressed through a range of regulatory exceptions and exemptions. As in the USA, the EMA has introduced a ‘compassionate use’ program, which allows access to new drugs and biological products (including stem cell products) outside of premarket clinical trials [23]. Unlike in the USA, however, EMA has also introduced a so-called ‘hospital exemption’ program for stem cell interventions. This program allows the provision of cellular medicinal products to individual patients “in a European hospital under the exclusive professional responsibility of a doctor” [22]. These hospital exemptions are authorized for use by the regulatory authority in the country in which the product is applied. As a result, the hospital exemption scheme has been implemented unevenly across EU member states [1]. In some countries, the scheme has been used to approve large numbers of experimental interventions and has created “the opportunity for a legal market of authorized stem cell therapy products to emerge within the province of the clinical professionalism” [24]. More recently, EMA has also introduced a “conditional market approval” scheme [25], which can be used also for stem cell interventions. According to this scheme, a stem cell product can be licensed at a later stage of a Phase III trial, when data collection for efficacy and safety has almost been completed.

Japan
Premarket evaluation of stem cell therapies in Japan was initially based on a similar regulatory model as in the USA and the EU. Until 2014, stem cell interventions were regulated under the Pharmaceutical Affairs Law (PAL) and treated either as pharmaceutical drug products, medical devices or combination products [26]. This regulatory pathway involved systematic multiphase trials and compliance with good clinical practice standards [26]. Then in May 2013, the Japanese National Diet passed the Regenerative Medicine Promotion Act (RMPA) [27], which formed the starting point of a radical regulatory reform. The RMPA was followed by the passing of the Amended PAL, which went into effect in November 2014 [28]. Under the amended PAL, the conditions for the clinical application of stem cell interventions changed significantly [26]. The amended law allowed for conditional, limited-term market approval of stem cell products after early-phase clinical trials. Conditional approval can occur after positive clinical data from as few as ten patients [29] provided these first-in-human trials demonstrate that the tested cell products are safe and ‘likely to predict efficacy’ [30]. Once approved by the Japanese Pharmaceuticals and Medical Devices Agency, clinical trial sponsors have the possibility to seek market approval for up to 7 years [30]. Clinical efficacy is tested in this time period in postmarketing procedures [31]. This is a significant shift away from the multiphase RCT system, which has emerged as the methodological gold standard in medicine research in the recent decades. This break, and the possibility to time-limited conditional market approval after evidence from small numbers of patients, is likely to have repercussions for the regulation of stem cell research in other countries, and possibly also other fields of medicine research.

It is also noteworthy that conditionally approved stem cell interventions are eligible for reimbursement by the Japanese health insurance system [26]. Costs for these experimental treatments are split between the state and patients at a ratio of 70:30 [30]. This is a drastic change to the financing of research and development.
costs for medicine research, which typically requires long-standing corporate or government investments before development costs could be amortized through health insurance reimbursement and consumer charges.

India

The governance of the clinical stem cell field in India started with the introduction of the Guidelines for Stem Cell Research and Therapy [32], a regulatory guidance document that was joint issued by the Indian Council of Medical Research and Department of Biotechnology in 2007 [33]. This regulatory guidance formally prohibited the use of stem cells in human patients, except in the context of formally approved clinical trials [33]. In practice, however, this approach was not consistently implemented and India became one of the countries in which unproven or nonsystematically tested stem cell interventions flourished on a large scale [5]. In order to address these problems, the Indian authorities issued a revised regulatory approach in 2013, laid down in the Guidelines for Stem Cell Research [34].

These guidelines reconfirmed the prohibition of nonapproved commercial applications with stem cells and stated that all clinical trials with stem cells had to be approved by the Drug Controller General India (DCGI). In 2014, the DCGI announced that stem cells were treated as a drug product and that clinical trials and premarket approval had to conform to the Indian Drugs and Cosmetics Act, which included a new section on stem cells [35]. With these adjustments, the regulation of clinical stem cell research was formally put under statutory law.

At the level of clinic practice, however, the situation remained diverse. Stem cell trials continue to be conducted outside of DCGI control and unapproved or nonsystematically proven stem cell interventions are still offered in many hospitals [36].

As a result of this uneven implementation, the current regulatory situation in India can best be described as flexible, and as serving multiple interests and stakeholder groups simultaneously [5]. On the one hand, the DCGI’s requirement for multiphase trials and international best practice standards facilitates formal approval and marketization of stem cell-based medicinal products at a national and international level. This is exemplified by the DCGI’s approval of the first stem cell product in May 2016, which shall soon also be marketed in the EU, in the context of the EMA’s orphan designation scheme [37]. On the other hand, the lack of coherent regulatory enforcement and the continued toleration of unapproved clinical applications [35] enables physician-based forms of innovation and localized forms of profit making outside of the regulatory system.

China

The development of a regulatory framework for clinical stem cell applications in China has been an ongoing process and much slower than, for instance, in the EU or the USA. As in India, a large market of experimental for-profit interventions with stem cells emerged in the early 2000s. Following an initial attempt to control the provision of these unproven or nonsystematically tested interventions in 2009, which failed [38], the Chinese health authorities introduced a regulatory white paper, in 2013, which formed the basis of a more comprehensive regulatory framework for clinical stem cell research that was publicized in August 2015 [39]. The 2015 Regulation for Clinical Stem Cell Research, jointly issued by the National Health and Family Planning Commission and the Chinese FDA, states that the clinical translation of stem cell-based approaches must occur through systematic clinical studies, which must follow from sound preclinical evidence. The core of this regulation is that stem cell trials can only be conducted in specifically authorized research hospitals and that for-profit applications of experimental stem cell interventions are legally prohibited. If this rule is implemented, this would mean the delimitation of clinical stem cell interventions to a small number of elite hospitals. It would also mean the systematic shutting down of numerous for-profit stem cell clinics [39]. While this evolving regulatory approach indicates an important step toward the improved review and governance of clinical stem cell research and applications in China, there are still numerous unresolved questions with this framework. A first set of questions concerns implementation: will the Chinese authorities have the political will to mobilize sufficient resources and administrative infrastructures to consistently implement this new regulatory model? Or will informal stem cell interventions continue to exist next to formally approved clinical trials and treatments, as in India and other countries? A second set of questions concerns the exact methodological requirements that will be required in premarket evaluations. In the 2015 guidelines, this point remained undefined. It is unclear whether stem cells shall be regulated as a pharmaceutical product or a medical technology, and also which types of clinical studies the National Health and Family Planning Commission and Chinese FDA require before approving routine clinical use. While the 2013 white paper mentioned Phase I–III trials, the 2015 regulation only speaks of clinical studies that shall be conducted according to ‘scientific principles’ [39]. This could well mean that China’s health regulators leave this question deliberately open so as to have the flexibility to follow the current Japanese model rather than the more costly USA or EU model.
Argentina
The clinical use of stem cells is currently regulated under the Ministerial Resolution No. 610/2007 from the Argentinean Ministry of Health (MOH). This resolution states that the use of human cells falls under the authority of the Unique Central Institute for Ablation and Implantation (INCUCAI). By falling under the authority of INCUCAI, stem cell interventions are not governed as a medical product (as in the EU, India and the USA) but as a medical procedure, which are managed by the Argentinean Transplant Act. With the exception of hematopoietic cell transplants from human bone marrow, all types of stem cells are considered experimental and require evaluation of safety and efficacy through clinical research [40,41]. In the late 2000s, a dispute emerged among Argentina’s regulators whether stem cells should also be regulated as a medical product. In that case, Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) would start to play a major role in regulation. A first step into this direction was achieved in 2011 by ANMAT regulation 7075/2011, in which more than minimally modified cellular products were classified as ATMPs. At present, however, ANMAT has no legal authority to enforce approval of stem cell treatments under its rule, and it has not been decided in which situation researchers should apply at ANMAT or INCUCAI. Because INCUCAI’s regulation does not discriminate between different cell types, specific procedures of cell manipulation or different levels of risks, the regulation could be considered so broadly as to include even human embryonic stem cells (hESCs) [40]. However, a new regulatory approach that will provide clarity on these issues is currently being drafted by the MOH, together with Argentina’s Advisory Committee on Stem Cells and Regenerative Medicine [42].

In practice, the legal reach of both INCUCAI and ANMAT is limited. Argentina is a federal country in which national regulatory authorities have legal power only when medical products cross provincial borders or are involved in foreign trade. As a result, federal regulations are not applicable at the provincial level as long as medical treatments or services are applied exclusively within the geographic jurisdiction of a province [40]. A situation exists where there is no effective control over stem cell-based clinical applications if these interventions are not offered or shipped across multiple provinces. According to estimates of policy experts and representatives of patient associations, this undefined regulatory gray area has resulted in the increase of experimental for-profit interventions with stem cells, which have been provided by at least ten private clinics in the country [43].

Brazil
The development of a regulatory framework for clinical stem cell research in Brazil has been challenging for two reasons: religious opposition to stem cell research, and a constitutional prohibition that bans the commercial use of human cells and tissues [44]. Religious protests first flared up in 2005, when the Brazilian Congress approved Law #11,105, which legitimized the use of hESC for research, including in clinical trials. According to this law, the regulation for the production and clinical use of hESC and other types of stem cells (with the exception of bone marrow transplants) fell under the responsibility of Brazil’s National Agency for Health Surveillance (ANVISA), the country’s national drug regulatory authority [44]. Yet, following a complaint by the Catholic church at the Brazilian Supreme Court, the authorization of the use of embryos for research purposes was suspended for 3 years. In 2008, a final verdict confirmed that the 2005 law was valid, and that hESC research could go ahead [45]. According to officials of ANVISA, this 3-year deliberation delayed the development of effective regulation also for other types of stem cells [44]. A first regulatory step for the clinical use of stem cells was issued by ANVISA in March 2011, in the form of ANVISA Board Resolution #9. However, this regulation specified solely the technical standards for the harvesting, derivation, processing, storage and quality controls for clinical use of stem cells. It did not address standards for clinical trials and market authorization. The reason for this was that the Brazilian constitution prohibits the commercialization of human body materials, including human cells and their derivatives [44]. As a result, market approval and commercial distribution have until to this moment not been permitted. Regulatory debates on this issue within ANVISA and the Brazilian MOH are ongoing. However, because ANVISA has since 2013 worked on a draft regulation for clinical trials for advanced cell products, it is expected that commercialization of stem cell products will ultimately be approved in Brazil [44]. One consequence of this constitutional prohibition is that the number of for-profit providers of experimental stem cell interventions has been much lower than in other countries [5].

Regulatory diversification: implications for regulatory harmonization
What can currently be observed in the regulatory landscape of stem cell research is a conflict between two central dynamics: the striving for international harmonization, on the one hand, and an increasing process of regulatory diversification, on the other hand. Attempts of regulatory harmonization are exemplified by the FDA–EMA–Health Canada ATMP cluster, which
since 2008 has focused on the convergence of regulatory protocols for cellular therapies between regulatory authorities in the USA, the EU and Canada [46]. Another example is the Cell Therapy Working Group of the International Pharmaceutical Regulators Forum (founded in 2011), which aims to establish best regulatory practices and to realize gradual regulatory harmonization in the cellular medicine field [47]. Like the FDA–EMA–Health Canada ATMP cluster, the Cell Therapy Working Group of the International Pharmaceutical Regulators Forum comprises primarily regulatory authorities from high-income countries, namely the USA, the EU, Canada, Australia, New Zealand, Singapore, Taiwan and South Korea [48].

On the other hand, and in contrast to these ongoing attempts of regulatory harmonization, we are witnessing an increasing dynamics of regulatory diversification. As this paper has shown, this shift toward diversification is exemplified by three central processes. First is the emergence of a growing number of regulatory exceptions and exemptions that were initiated by drug regulatory authorities in high-income countries. These exceptions/exemptions facilitate processes of clinical translation, and sometimes commercial clinical applications [24], outside of the multiphase trial system, but within the confines and review procedures of national regulatory agencies. Salter et al. have described this process as a form of ‘hegemonic adjustment,’ through which national governments have altered regulatory frameworks and clinical methodologies to enable greater responsiveness to health consumer needs [24].

A second process of diversification is flexible enforcement of regulatory rules in some countries, in particular the toleration of clinical for-profit interventions with stem cells outside of the review and control structures of regulatory agencies. This has happened for years in India and China [49], and in recent years increasingly also in the USA [47], where governments responded only gradually to a flourishing gray-area market of stem cell interventions [49,50]. Unapproved-for-profit applications continue to be tolerated in these countries also after the introduction of national regulatory frameworks, which formally prohibit these experimental interventions. This is the case in both China and India, where large private hospitals and medical corporations continue to offer their services on the internet and seek to attract ‘medical tourists’ from all over the world [5,51–52]. Sloebboom-Faulkner et al. have interpreted this ‘flexible’ or ‘dual’ regulatory approach as an attempt of national governments to serve the interests of domestic and international elite scientists and corporations on the one hand (by introducing regulatory frameworks that comply with EBM and international best-practice standards), and the interests of less well-funded local researchers and companies on the other hand (by tolerating gray-area clinical applications and business practices exterior to formal regulatory rules) [3,49]. It is of interest that the tolerance of unapproved stem cell interventions has not been restricted to middle-income countries but could also be observed in the USA, where regulators took a surprisingly relaxed approach to many DTC stem cell clinics [50]. According to Turner and Knoepfler, there are currently more than 350 US businesses offering unapproved DTC interventions with stem cells. These businesses use both allogenic and autologous cells (including xenogeneic and self-proclaimed ‘induced pluripotent stem cells’ and ‘hESCs’) for a variety of conditions ranging from amyotrophic lateral sclerosis, Alzheimer’s and other neurodegenerative diseases, to cardiac diseases, pulmonary disorders and also cosmetic applications [50]. This development is partly driven by a growing number of rights-to-try laws in now more than 20 US states, and widespread calls for deregulation from various patient organizations [53]. However, as Turner and Knoepfler suggest, entrepreneurial physicians offering stem cell interventions may also have been emboldened by regulatory inactivity from the side of the FDA [50].

A third process of regulatory diversification in the stem cell field is characterized by the complete abandoning of the multiphase trial EBM system, as has happened in Japan. This model, as Sipp has pointed out, dramatically relaxes the need to demonstrate the clinical utility of cellular products prior to marketing, and raises critical questions regarding the testing of treatment efficacy [30]. According to Sipp, with this new approach “Japan clearly hopes to compete and succeed in the race to build a regenerative medicine industry by flattening a few hurdles” [50]. It is not unlikely that other countries will follow the Japanese regulatory model, or at least create new types of regulatory exceptions in which (conditional) market approval of stem cell treatments can be granted without preceding Phase I–III trials. However, as the case of Brazil illustrates, processes of regulatory heterogeneity are not exclusively driven by economic considerations or global competition. In Brazil, divergence from US and EU regulatory models has been caused by religious concerns and a constitutional prohibition to marketize human cell and tissue products. While this situation has not prevented the use of RCT methodology, it has precluded corporate-sponsored trials and participation of Brazilian hospitals and companies in multicountry licensing procedures.

Taken together, the absence of globally shared international regulatory standards for stem cell medicine, and the high level of regulatory diversification that is
resulting from differences in national policies as well as ambiguities that stem from emerging or unclear regulatory arrangements, has created crucial challenges for international clinical trial collaborations and cross-country marketing procedures.

Challenges for multicountry stem cell trials

We will now highlight four challenges that result from the above-mentioned situation of regulatory diversification. The first problem is that regulatory variation necessitates ongoing in-depth research into the (changing) regulatory conditions of drug regulatory authorities in several countries. For corporate sponsors and clinical investigators, the diversified and rapidly changing regulatory situation in the stem cell field is often perplexing and gives rise to important organizational problems [54]. What is required is a comparative, long-term engagement with the review and approval criteria of the regulatory agencies in all countries in which a clinical study shall be executed. Differences between regulatory rules in these countries must be singled out at an early stage, so as to design clinical trial protocols that conform to multi-jurisdictional frameworks. This is a time-consuming process that is complicated further by language barriers, cultural differences and differences in the ways in which regulatory requirements are enforced [55]. It is complicated further because different types of cells and stem cells are often regulated by different government agencies and different regulatory requirements and rules [56].

A second problem is that the need to interact with multiple regulatory authorities creates a high degree of organizational complexity [54,57]. To apply for trials and market approval in multiple countries requires time, money, specialist staff and a substantial administrative infrastructure. This is of course a general problem for clinical trials, not only for stem cell trials. However, because most stem cell trials are sponsored by academic investigators and small-to-mid size biotechnology companies, who have typically very limited resources, it is often difficult to meet the organizational requirements of multicountry trials, and even more so for researchers and corporations in low or middle-income countries [58].

A third challenge is that evolving or insufficiently defined regulatory procedures can impose significant delays, unexpected costs and uncertainties regarding the planning and conduct of clinical trials [54]. In countries where formal jurisdictional frameworks for cell- and stem cell-based clinical interventions are not yet in place or are in an early development phase, the situation can be even more challenging. Drug regulatory authorities may either postpone or completely reject incoming investigational new drug applications. Emerging or unclear regulatory procedures for the development of stem cell treatments may cause severe problems to international clinical research partnerships. Unresolved regulatory conditions can result in year-long delays, increase costs and give rise to the need to relocate a trial to another country or region, necessitating yet more regulatory applications.

A final problem is that regulatory differences between jurisdictions require extensive forms of self-governance, capacity building, training of clinical trial staff and often far-reaching changes of locally evolved conditions and practices in participating trial sites [54,59]. The reason for this is that regulatory variation between countries has a direct impact on the research practices, clinical methodologies and for-profit strategies that are employed in local hospitals and research institutes. These differences (at the level of local institutions and practices) have to be identified and addressed, so as to warrant standardized implementation of clinical trial protocols and acceptance of clinical data by multiple regulatory agencies. In some countries, knowledge and experience on the conduct of multiphase RCTs is also limited among clinical researchers [60]. These discrepancies between countries, hospitals (and often also within hospitals) endanger the scientific integrity of stem cell-based multicountry trials and have to be tackled at an early stage of the clinical translation process [61]. To mitigate this challenge, intensive training of staff and changes in local research practices are required, so that clinical protocols can be implemented in a standardized and trustworthy way [54]. Unless adequate finance for these forms of scientific self-governance, training and education is set aside, the conduct of international multicenter stem cell trials remains a risky undertaking.

Conclusion

With a rising number of stem cell-based strategies entering the clinical development phase, the demand for international stem cell trials is growing. This article has shown, however, that the high level of regulatory diversity in the stem cell field provides important obstacles to the organization of multicountry stem cell clinical trials. Emerging and unclear regulations in some countries, and the absence of internationally harmonized regulatory frameworks, confront investigators with unexpected costs, time delays or even the need to relocate a trial to another country or region. These factors, especially increased or unexpected costs, are likely to reduce possibilities of researchers in low- and middle-income countries to participate in the stem cell
market, and they are also likely to increase the market price of successfully proven stem cell treatments. The high level of regulatory heterogeneity in the stem cell field gives rise to a high level of administrative complexity and requires far-reaching forms of scientific self-governance, training and the creation of effective coordination and monitoring structures. These forms of self-governance and capacity building constitute a fundamental precondition to successfully navigate through a diverse and internationally nonharmonized regulatory environment. It is important to note, in this respect, that the implementation of standardized clinical research protocols is more difficult to achieve in the field of stem cell medicine than in other – more established – areas of medicine research. The key reason for this – aside from the issue of regulatory heterogeneity – is the lack of well-established international clinical research platforms. In oncology research, for instance, long-standing international clinical research infrastructures have evolved over the course of several decades. These transnational platforms have developed their own centralized institutions that are responsible for the coordination of all successive steps of the clinical translation process, including controls of processes of data collection, recording and analysis [62]. In the stem cell field, however, such infrastructures are only gradually emerging. While international projects such as the China SCI Net [63] show that multicountry clinical research platforms are evolving, this article has illustrated that these processes are complicated by the absence of internationally harmonized regulatory frameworks. The existence of strongly diverging regulatory, institutional and clinical research cultures across countries and regions makes the performance of standardized multicountry trials a challenging and risky organizational enterprise.

Future perspective

The process of regulatory diversification in regenerative medicine research, which has been described in this article, is likely to continue and deepen. With a growing number of regulatory alternatives in the EU [1] and the USA [11,50], and the introduction of conditional, limited-term market approval of stem cell products after early-phase trials in Japan [30], the EBM paradigm of medical research (with the multiphase trial system at its core) seems to gradually lose its hegemonic status [24]. It remains to be seen whether other countries will follow the Japanese regulatory model. However, the emergence of parallel (and potentially incommensurable) regulatory zones and networks [2–3,49], in which researchers and companies can choose between different regulatory options to bring stem cell-based treatments to the clinic and market is possible.

Of interest is that regulatory heterogeneity in the stem cell field is not only emerging between countries (and in relation to global differentials of wealth, healthcare as well as scientific and regulatory resources [3]) but increasingly also within national jurisdictions in high-income countries [1,11,50,53]. In the light of the growing pressure from patient organizations, international scientific and economic competition, and an increasing market of gray area stem cell interventions [5,49,53] the shift toward more rapid, flexible and less rigorous procedures of market approval is likely to continue in many countries, including in the USA and the EU.

With the increase of regulatory divergence at both national and international levels [2], various questions remain critical. What is the impact of the diversification of regulatory arrangements on the credibility of stem cell therapies, and how do actors determine which standards and products they can trust? Can the scientific and safety standards of medicine research that have evolved during the last few decades (and which have prevented large numbers of patients worldwide from exposure to fraudulent medicines and intolerable risks) be maintained under the alternative regulatory pathways that are currently emerging? Considering the reputational, financial and health risks of less stringent regulation, the assumption that rapid market approval produces economic advantages, may well prove wrong. Moreover, the adoption of stem cell therapies into national health insurance that lack solid proof of efficacy is likely to prevent access to other treatments and to take away resources for research and development that may be of greater value in the long run [30]. In the light of these challenges, societies and policy makers are now confronted with the difficult task to find ways and criteria to systematically evaluate methodological alternatives, and to halt them if they are likely to give rise to irresponsible forms of clinical validation, unreliable evidence or (in the most extreme case) the legitimization of for-profit scams. Whether and to what extent policy organs will do so, depends on the political prioritization of this problem, and on the will to mobilize the resources, expertise and administrative infrastructures that are required to perform this task.

Financial & competing interests disclosure

This article has benefited from research support provided by the ERC (283219) and the ESRC (ES/I018107/1). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Executive summary

- The regulatory conditions through which stem cell-based medicinal interventions are translated from the laboratory bench to the clinic and the market are undergoing a significant process of diversification.
- This process has far-reaching consequences for international regulatory harmonization and the organization of multicountry clinical trial collaborations.

Regulatory comparison

- The article explores these issues by examining regulatory developments in seven jurisdictions: Argentina, Brazil, China, the EU, India, Japan and the USA.

Regulatory diversification: implications for regulatory harmonization

- Regulatory diversification is exemplified by three central processes:
  - A growing number of regulatory exemptions in many countries, which allow for clinical applications outside of the hegemonic multiphase trial system;
  - Lenient enforcement of regulatory rules in many countries, which have resulted in the widespread toleration of experimental for-profit practices outside of the approval and review mechanisms of drug regulatory authorities;
  - The development of entirely new regulatory models, which have abandoned the use of multiphase trials as a critical passage point for market approval.
- These developments make processes of multicountry market approval of stem cell-based therapies increasingly difficult.

Challenges for clinical trial collaborations

- The absence of shared regulatory standards for stem cell medicine has created important challenges for international clinical trial collaborations.
- These challenges range from increased costs, time delays, to a high level of administrative complexity and the need for extensive forms of scientific self-governance, staff training and the requirement of effective coordination and monitoring structures (which are necessary to compensate for regulatory gaps between countries).
- These problems are likely to prevent medical progress and make the conduct of standardized multicountry trials to a challenging and risky organizational enterprise.
- They are also likely to delay patients’ access to clinically proven stem cell therapies in many countries.

References

10. FDA. Regulation for human, cellular and tissue products (HCT/Ps) [72 FR 33667] (2007). www.fda.gov/OHRMS/DOCKETS
12. FDA. Fast track approval. www.fda.gov/ForPatients/Approvals/Fast
13. FDA. Accelerated approval. www.fda.gov/ForPatients/Approvals
15. FDA. Priority review. www.fda.gov/ForPatients/Approvals/Fast
16. FDA. Expanded access. www.fda.gov/NewsEvents/PublicHealthFocus
17. FDA. Subpart 1: expanded access to investigational drugs for treatment use. www.ecfr.gov/cgi-bin
Perspective

Rosemann, Vasen, Bortz & Sleeboom-Faulkner

20 STAT. FDA moves to crack down on unproven stem cell therapies.
www.statnews.com/2016/02/08

www.ema.europa.eu/ema/index

www.eurostemcell.org/commentanalysis

23 EMA. Compassionate use.
www.ema.europa.eu/ema


25 EMA. Conditional market authorization.
www.ema.europa.eu/ema/index


31 Miyata T. Regulatory and legal frameworks for offering stem cell therapies in Japan (2013).
www.nationalacademies.org/hmd


34 Indian Council of Medical Research. Guidelines for stem cell research (2013).
icmr.nic.in/stem_cell_guidelines.pdf


37 Jayaramam KS. India’s first stem cell based drug (2016).
www.natureasia.com/en/india/article


40 Arzuaga FC. Stem cell research and therapies in Argentina: the legal and regulatory approach. Stem Cells Dev. 22(Suppl. 1), 40–43 (2013).


www.mincyt.gob.ar/_post


www.i-p-r-f.org/index.php/en/working-groups

www.i-p-r-f.org/files/4714/5387/8143


www.ncbi.nlm.nih.gov/books/NBK201975/


China SCI Net. www.chinascinet.org